Ossip Groth: Die Seite wurde neu angelegt: „Entstehender Artikel {| class="wikitable" | | bgcolor="#dfdfdf" | '''Siehe auch''' | align="left" width="800" | |- | bgcolor="#d…“

2010-04-06T17:38:39Z

Die Seite wurde neu angelegt: „miniatur|Entstehender Artikel {| class="wikitable" | | bgcolor="#dfdfdf" | '''Siehe auch''' | align="left" width="800" | |- | bgcolor="#d…“

Neue Seite

[[Datei:pptpdtjpg1.png|miniatur|Entstehender Artikel]]
{| class="wikitable" |
| bgcolor="#dfdfdf" | '''Siehe auch'''
| align="left" width="800" |
|-
| bgcolor="#dfdfdf" | '''Freie Übersichtsartikel'''
| align="left" width="800" |
<ref name="PMID17652153">Frontiers in glucagon-like peptide-2: multiple actions, multiple mediators. Am J Physiol Endocrinol Metab 293(2):E460-5 (2007) PMID 17652153 </ref><ref name="PMID15271645">Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 287(2):E199-206 (2004) PMID 15271645 </ref><ref name="PMID15140755">Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes. Am J Physiol Endocrinol Metab 286(6):E882-90 (2004) PMID 15140755 </ref><ref name="PMID15140754">Glucagon-like peptide 1 agonists and the development and growth of pancreatic beta-cells. Am J Physiol Endocrinol Metab 286(6):E875-81 (2004) PMID 15140754 </ref><ref name="PMID18227398">New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond. Circulation 117(4):574-84 (2008) PMID 18227398 </ref><ref name="PMID15561911">The incretin approach for diabetes treatment: modulation of islet hormone release by GLP-1 agonism. Diabetes 53 Suppl 3():S197-204 (2004) PMID 15561911 </ref><ref name="PMID15561910">Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. Diabetes 53 Suppl 3():S190-6 (2004) PMID 15561910 </ref><ref name="PMID15331525">Therapeutic strategies based on glucagon-like peptide 1. Diabetes 53(9):2181-9 (2004) PMID 15331525 </ref><ref name="PMID12475787">The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes 51 Suppl 3():S434-42 (2002) PMID 12475787 </ref><ref name="PMID17337495">Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care 30(6):1335-43 (2007) PMID 17337495 </ref><ref name="PMID17337494">Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications. Diabetes Care 30(6):1344-50 (2007) PMID 17337494 </ref><ref name="PMID16443905">Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. Diabetes Care 29(2):435-49 (2006) PMID 16443905 </ref><ref name="PMID19036624">The incretins: from the concept to their use in the treatment of type 2 diabetes. Part A: incretins: concept and physiological functions. Diabetes Metab 34(6 Pt 1):550-9 (2008) PMID 19036624 </ref><ref name="PMID18640591">DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients? Diabetes Metab 34 Suppl 2():S91-5 (2008) PMID 18640591 </ref><ref name="PMID18640590">Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies. Diabetes Metab 34 Suppl 2():S78-90 (2008) PMID 18640590 </ref><ref name="PMID18640589">GLP-1 receptor signaling: effects on pancreatic beta-cell proliferation and survival. Diabetes Metab 34 Suppl 2():S73-7 (2008) PMID 18640589 </ref><ref name="PMID18640588">Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. Diabetes Metab 34 Suppl 2():S65-72 (2008) PMID 18640588 </ref><ref name="PMID16142014">Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes Metab 31(3 Pt 1):233-42 (2005) PMID 16142014 </ref><ref name="PMID14645210">Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology 144(12):5145-8 (2003) PMID 14645210 </ref><ref name="PMID18322302">Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control? Eur J Endocrinol 158(6):773-84 (2008) PMID 18322302 </ref><ref name="PMID11124853">Glucagon-like peptide-1: a major regulator of pancreatic beta-cell function. Eur J Endocrinol 143(6):717-25 (2000) PMID 11124853 </ref><ref name="PMID18628530">Incretin-based therapies in type 2 diabetes mellitus. J Clin Endocrinol Metab 93(10):3703-16 (2008) PMID 18628530 </ref><ref name="PMID18258781">The GLP-1 concept in the treatment of type 2 diabetes--still standing at the gate of dawn? J Clin Endocrinol Metab 93(2):375-7 (2008) PMID 18258781 </ref><ref name="PMID11297614">Glucagon-like peptide 2. J Clin Endocrinol Metab 86(4):1759-64 (2001) PMID 11297614 </ref><ref name="PMID17200703">The role of gut hormones in glucose homeostasis. J Clin Invest 117(1):24-32 (2007) PMID 17200703 </ref><ref name="PMID17622601">Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 298(2):194-206 (2007) PMID 17622601 </ref><ref name="PMID16830359">Gut hormones, and short bowel syndrome: the enigmatic role of glucagon-like peptide-2 in the regulation of intestinal adaptation. World J Gastroenterol 12(26):4117-29 (2006) PMID 16830359 </ref>
|-
| bgcolor="#dfdfdf" | '''Wichtige Übersichtsartikel'''
| align="left" width="800"|
|-
| bgcolor="#dfdfdf" | '''Medline Suchterm/ Synonyme'''
| align="left" width="800"|
|-
| bgcolor="#00dfdf" | '''Was ist das'''
| align="left" width="800"|
|-
| bgcolor="#dfdfdf" | '''Struktur'''
| align="left" width="800"|
|-
| bgcolor="#dfdfdf" | '''Physiologie'''
| align="left" width="800"|
|-
| bgcolor="#dfdfdf" | '''Knockout'''
| align="left" width="800"|
|-
| bgcolor="#dfdfdf" | '''Transgen'''
| align="left" width="800"|
|-
| bgcolor="#dfdfdf" | '''Mutation'''
| align="left" width="800"|
|-
| bgcolor="#dfdfdf" | '''Polymorphismus'''
| align="left" width="800"|
|-
| bgcolor="#dfdfdf" | '''Genexpression'''
| align="left" width="800"|
|-
| bgcolor="#dfdfdf" | '''Inhibitoren'''
| align="left" width="800"|
|-
| bgcolor="#dfdfdf" | '''Agonisten'''
| align="left" width="800"|
|}

----

== Bibliographie ==
<references />

{{LinkWP_Miniartikel|Txt=Inkretin|Link=Inkretin-Effekt}}

Inkretin - Versionsgeschichte

Ossip Groth: Die Seite wurde neu angelegt: „Entstehender Artikel {| class="wikitable" | | bgcolor="#dfdfdf" | '''Siehe auch''' | align="left" width="800" | |- | bgcolor="#d…“